Theralase Releases Peer-Reviewed Research on Anti-Cancer Memory Response and Destruction of Cancerous Cells
June 24 2014 - 5:59AM
Access Wire
Toronto, Ontario / ACCESSWIRE / June 24,
2014 / Theralase Technologies Inc.
("Theralase") (TSXV: TLT)
(TLTFF: OTC Link(R)) announced today that it has
publicly released two significant peer-reviewed research papers
concerning the destruction of cancer.
The first paper demonstrates
the vaccine and immune "memory response" effects of Theralase's
lead Photo Dynamic Compound (PDC), in the destruction of cancer in
an animal model. The second paper demonstrates the effectiveness of
Theralase's anti-cancer technology in destroying both normoxic
(normally oxygenated) cancerous cells and hypoxic (low oxygenated)
cancerous cells.
Theralase's Vaccine and Immune
Memory Response:
Theralase's research
discovered that its lead Photo Dynamic Compound (PDC),
intended for the destruction of cancer, demonstrated an ability to
render animals immune to repeated exposures of the same cancer. At
the 37th Annual American Society for
Photobiology on June 16, 2014, in San Diego, California, this
peer-reviewed research was presented via poster submission,
entitled, "Elicitation of Tumor-free Long-term Survival and
Long-lasting Antitumor Memory with Novel Non-immunosuppressive
Near-Infrared PDT"
Theralase's Destruction of
Normal and Low Oxygenated Cancer Cells:
As cancerous tumors grow and
advance in stage, they can develop areas of hypoxia and even
hypoxic cores. These hypoxic areas and cores become resistant to
treatment by ionizing radiation and other forms of treatment,
including traditional Photo Dynamic Therapy (PDT). By developing
state-of-the-art PDC technology that is able to destroy both
normoxic and hypoxic cancerous cells, these findings strongly
suggest the potential for future application of Theralase's
anti-cancer technology to a wide variety of cancers.
"Harnessing of novel visible
and near-infrared light photoactivated, Type II/Type I, tunable,
metal-based, small molecule, coordination complexes in PDT", was
presented at the conference and details how two additional
Theralase PDCs were able to work in both normoxic and hypoxic
conditions, strongly suggesting that these PDCs may be suitable in
the treatment of more complex, solid core tumors that present with
hypoxic areas or hypoxic cores, such as later stage or more
developed cancers.
This research has been posted to Theralase's corporate
website at http://www.theralase.com/www2/pdf/elicitation.pdf
and http://www.theralase.com/www2/pdf/harness.pdf
for review or www.theralase.com under the
Press tab.
Dr. Arkady Mandel, Chief
Scientific Officer of Theralase stated, "In the first
presentation, Theralase's
preclinical trials prove that it is possible to generate a
long-term anti-cancer memory response in animals. For
the first time in our research program, we have demonstrated that
Near Infrared (NIR) PDT leads to long standing clearance of
colon cancer cells, but also provides long
lasting protection against further tumour cell challenge in young
(eight to ten weeks old) and older (ten to eleven month old)
mice. This is the
first step toward the long-term goal of developing an affordable
and practical vaccine to prevent cancer recurrence. The next steps
are to further validate this research with additional animals and
different cancer cell lines and then translate this research into a
human clinical trial. We are collaborating with experts in medical
biophysics, immunology and clinical oncology from various
internationally acclaimed clinical research institutes to further
advance this remarkable platform technology. In the second
presentation, Theralase demonstrates an ability of its PDC
technology to effectively destroy both normoxic and hypoxic
cancerous cells. This suggests an application of this
technology to virtually all cancers,
including later stage cancers that present with hypoxic areas and
cores that can prove resistant to most forms of
treatment."
Roger Dumoulin-White,
President and CEO of Theralase stated, "If our PDC technology is
proven effective in cancer patients, through human clinical trials
slated to commence in early 2015, the implications of this
discovery are game changing for both Theralase and for the cancer
patients affected. As demonstrated in the first research paper, the
ability to destroy the original cancer and also program the body's
immune system to prevent its recurrence, after only a single
treatment, is nothing short of miraculous. In the second research
paper, demonstration of the ability to destroy virtually all types
of cancers, whether normoxic or hypoxic in nature, opens up the
potential of new treatment options for a wide range of cancers in
various early and advanced stages."
About Theralase Technologies Inc.
Founded in 1994, Theralase
Technologies Inc. ("Theralase") (TSXV: TLT) (TLTFF: OTC Link(R))
designs, manufactures and markets patented super-pulsed laser
technology which is used for the elimination of pain, reduction of
inflammation and dramatic acceleration of tissue healing. Theralase
has sold over 800 systems in Canada and over 400 systems in the US
and international markets to licensed healthcare practitioners such
as: medical doctors, chiropractors, physical therapists and
athletic therapists. Theralase has been so successful in healing
nerve, muscle and joint conditions in clinical practice that
Theralase's scientists are now investigating the application of its
lasers in the destruction of cancer using specially designed
molecules called Photo Dynamic Compounds (PDCs) which localize to
the DNA of cancer cells and then, when activated by light, destroy
the cancer cells.
Additional information is
available at www.theralase.com and
www.sedar.com .
This press release contains
forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies
Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
Melony Jamieson - Get it Done
416-518-6355
melony@getitdone.ca
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Aug 2023 to Aug 2024